|
|
 Previous Article | Table of Contents | Next Article 
RAPID COMMUNICATION
Stimulation of Hematopoiesis by Amifostine in Patients With Myelodysplastic Syndrome
Alan F. List,
Farah Brasfield,
Ruth Heaton,
Betty Glinsmann-Gibson,
Linda Crook,
Raymond Taetle, and
Robert Capizzi
From the Section of Hematology/Oncology and the Bone Marrow Transplant Program, The Arizona Cancer Center, University of Arizona, Tucson; and U.S. Bioscience, West Conshohocken, PA.
The aminothiol, amifostine (Ethyol; U.S. Bioscience, West Conshohocken, PA), is a cytoprotective agent that ameliorates the toxicities of anticancer therapy. In vitro, amifostine promotes the formation and survival of primitive hematopoietic progenitors derived from myelodysplastic bone marrow (BM) specimens. To evaluate the hematological effects of amifostine, 18 patients with myelodysplastic syndrome (MDS) and one or more refractory cytopenias received treatment with amifostine in a Phase I/II study. Four cohorts received intravenous treatment with 100, 200, or 400 mg/m2 amifostine three times a week, or 740 mg/m2 weekly for three consecutive weeks followed by 2 weeks observation. Nonresponding patients received a second course of therapy at the next higher dose level depending upon drug tolerance. Bone marrow (BM) progenitor growth was assessed before treatment and after day 21. Diagnoses included refractory anemia (7), refractory anemia with ringed sideroblasts (5), refractory anemia with excess blasts (RAEB) (4), and RAEB-in transformation (RAEB-t) (2). Single- or multi-lineage hematologic responses occurred in 15 patients (83%) treated with the three-times-a-week dose schedule. Fourteen patients had a 50% or greater increase in absolute neutrophil count with amifostine treatment (range, 426 to 11,348/µL). Platelet count increased in 6 (43%) of 14 patients with thrombocytopenia (absolute increase, 16,000 to 110,000/µL), and 5 of 15 red blood cell transfusion-dependent patients had a 50% of greater reduction in transfusion needs. Assayable hematopoietic progenitors increased in 13 of 15 evaluable patients; including CFU-GEMM (12), BFU-E (8), and CFU-GM (6). Amifostine doses less than or equal to 200 mg/m2 were well tolerated, whereas grade II nausea, vomiting, and fatigue was limiting at higher doses. Three patients with excess blasts before enrollment experienced an increase in BM blast percentage and two patients had evolution to acute leukemia that persisted after treatment withdrawal. We conclude that amifostine administered at doses  200 mg/m2 three times a week is well tolerated and has hematologic activity in patients with MDS.
Blood, Vol. 90 No. 9 (November 1), 1997:
pp. 3364-3369
© 1997 by The American Society of Hematology.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. P. Steensma and J. M. Bennett
The Myelodysplastic Syndromes: Diagnosis and Treatment
Mayo Clin. Proc.,
January 1, 2006;
81(1):
104 - 130.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A.-M. Tsimberidou, F. J. Giles, I. Khouri, C. Bueso-Ramos, S. Pilat, D. A. Thomas, J. Cortes, and R. Kurzrock
Low-dose interleukin-11 in patients with bone marrow failure: update of the M. D. Anderson Cancer Center experience
Ann. Onc.,
January 1, 2005;
16(1):
139 - 145.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. C. Acosta, C. Richard, M. D. Delgado, M. Horita, M. G. Rizzo, J. L. Fernandez-Luna, and J. Leon
Amifostine impairs p53-mediated apoptosis of human myeloid leukemia cells
Mol. Cancer Ther.,
September 1, 2003;
2(9):
893 - 900.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. F. List
New Approaches to the Treatment of Myelodysplasia
Oncologist,
April 1, 2002;
7(90001):
39 - 49.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson, J. M. Bennett, H. Kantarjian, C. A. Schiffer, S. D. Nimer, B. Lowenberg, R. M. Stone, M. Mittelman, G. F. Sanz, P. W. Wijermans, et al.
Myelodysplastic syndromes standardized response criteria: further definition
Blood,
September 15, 2001;
98(6):
1985 - 1986.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Raza, P. Meyer, D. Dutt, F. Zorat, L. Lisak, F. Nascimben, M. du Randt, C. Kaspar, C. Goldberg, J. Loew, et al.
Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes
Blood,
August 15, 2001;
98(4):
958 - 965.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. D. Cheson, J. M. Bennett, H. Kantarjian, A. Pinto, C. A. Schiffer, S. D. Nimer, B. Lowenberg, M. Beran, T. M. de Witte, R. M. Stone, et al.
Report of an international working group to standardize response criteria for myelodysplastic syndromes
Blood,
December 1, 2000;
96(12):
3671 - 3674.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Jahnukainen, M. Hou, M. Parvinen, S. Eksborg, and O. Söder
Stage-Specific Inhibition of Deoxyribonucleic Acid Synthesis and Induction of Apoptosis by Antracyclines in Cultured Rat Spermatogenic Cells
Biol Reprod,
August 1, 2000;
63(2):
482 - 487.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
P. Wijermans, M. Lubbert, G. Verhoef, A. Bosly, C. Ravoet, M. Andre, and A. Ferrant
Low-Dose 5-Aza-2'-Deoxycytidine, a DNA Hypomethylating Agent, for the Treatment of High-Risk Myelodysplastic Syndrome: A Multicenter Phase II Study in Elderly Patients
J. Clin. Oncol.,
March 1, 2000;
18(5):
956 - 956.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. D. Preisler, B. Li, J. Yang, R. W. Huang, E. Devemy, P. Venugopal, M. Tao, H. Chopra, S. A. Gregory, S. Adler, et al.
Suppression of Telomerase Activity and Cytokine Messenger RNA Levels in Acute Myelogenous Leukemia Cells in Vivo in Patients by Amifostine and Interleukin 4
Clin. Cancer Res.,
March 1, 2000;
6(3):
807 - 812.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
A. Raza, H. Qawi, L. Lisak, T. Andric, S. Dar, C. Andrews, P. Venugopal, S. Gezer, S. Gregory, J. Loew, et al.
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone
Blood,
March 1, 2000;
95(5):
1580 - 1587.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Hellstrom-Lindberg, C. Willman, A. J. Barrett, and Y. Saunthararajah
Achievements in Understanding and Treatment of Myelodysplastic Syndromes
Hematology,
January 1, 2000;
2000(1):
110 - 132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. F. Romano, A. Lamberti, R. Bisogni, C. Garbi, A. M. Pagnano, P. Auletta, P. Tassone, M. C. Turco, and S. Venuta
Amifostine Inhibits Hematopoietic Progenitor Cell Apoptosis by Activating NF-kappa B/Rel Transcription Factors
Blood,
December 15, 1999;
94(12):
4060 - 4066.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
